Mean platelet volume: ready for prime time?

Mean platelet volume: ready for prime time?

Tomás Benito-González, Rodrigo Estévez-Loureiro

Interventional Cardiology Unit, University Hospital of Leon, Leon, Spain

Correspondence to: Rodrigo Estévez-Loureiro, MD, PhD, FESC. Department of Cardiology, Complejo Asistencial Universitario de León, Altos de Nava SN, 24071 León, Spain. Email:

Submitted Oct 03, 2016. Accepted for publication Oct 11, 2016.

doi: 10.21037/jtd.2016.11.99

Coronary artery disease (CAD) represents a leading cause of death worldwide despite current advances in drug and revascularization therapies. Given it adverse prognosis, risk stratification of patients with an acute coronary syndrome (ACS) remains a challenging issue. In this regard, different biomarkers are becoming more and more important in diagnosis assessment and outcome prediction.

Platelets play a key role in the pathogenesis of ACS, especially in the setting of atherothrombotic acute myocardial infarction (AMI) with occlusion of the infarct-related artery by a platelet-rich clot (1). Circulating platelets are heterogeneous in size, density and reactivity, and changes in these variables are important for the development of an ACS (2).

Mean platelet volume (MPV) represents a quick approach to the variability in size of circulating platelets and is an easy measurable and inexpensive parameter usually included in routine blood test (3). MPV may reflect platelet load of containing granules and is deemed to be an indicator of platelet function and reactivity (4). Larger platelets seem to be more active from a metabolic and enzymatic point of view, thus having a higher thrombotic potential (5). Specifically, larger platelets were found to be denser and have enhanced aggregability, releasing greater amounts of thromboxane A2 and B2, serotonin and β-thromboglobulin, and expressing more adhesion surface proteins (6-9).

Regarding ischemic heart disease (IHD), MPV was proved to be higher in patients with ACS, with an apparent stepwise decrease from AMI to unstable angina to stable chronic coronary disease or non ACS patients (10). This finding can be explained as an expression of enhanced platelet reactivity in the acute setting of IHD and suggests that MPV could be useful in the evaluation of patients with chest pain (11).

Furthermore, MPV has shown prognostic value in patients with CAD. Goncalves et al. reported that elevated MPV was a strong independent predictor of long-term outcomes (death and AMI) after percutaneous coronary intervention, with a comparable predictive value to troponin in patients with an ACS (12).

Huczek et al. informed that high MPV was associated with impaired angiographic reperfusion (no-reflow phenomenon) and increased 6-month mortality in patients undergoing primary percutaneous coronary intervention (13). Estévez-Loureiro et al. published that increased MPV was an independent predictor of infarct-related artery patency in patients with acute ST-segment elevation myocardial infarction treated with primary angioplasty (14). On the contrary, platelet count itself did not show any diagnostic nor prognostic value in patients with ACS (15). All these findings have been confirmed in later studies and systematic reviews. Chu et al. pooled results from three cohort studies involving 3,184 patients with AMI and concluded that elevated MPV (two studies used a cut-off MPV of ≥10.3 fL and the other >9 fL) increased the odds of death as compared with a normal MPV (11.5% vs. 7.1%; OR, 1.65; 95% CI, 1.12–2.52, P=0.012) (16). Moreover, recent studies showed prognostic implications of raised MPV beyond IHD (17).

Sun et al. enrolled more than eighteen hundred Chinese patients with ST-segment elevation AMI along almost 6 years (18). In this study, patients were classified in four groups according to their MPV in the laboratory tests on admission, with most cases within established normal values (9.5–12.5 fL). Subjects with higher MPV tended to be older and have higher levels of triglyceride, low density lipoprotein cholesterol and white blood cell count, and presented greater prevalence of prior AMI. These findings already point out that elevated MPV was related to a higher-risk population. During a mean follow up of over 4 years, worst outcomes occurred among patients with larger MPV, either above the normal range (>12.5 fL) or in higher values within the normal range (11.1–12.5 fL). After adjustment of other factors independently associated with survival, increased MPV remained as an independent predictor of all-cause mortality in Cox regression model (MPV =11.1–12.5 fL, HR, 1.38, 95% CI, 1.20–1.68; MPV >12.5 fL, HR, 1.72, 95% CI, 1.41–1.96). Although relationship of MPV and cardiac death was not specifically assessed in this study, most of documented events (144 out of 197) during follow-up were due to cardiovascular issues. As authors already commented in their article, this study is limited due to single-center and retrospective enrollment. Moreover, some well-known prognostic factors in the scenario of an ACS, such as troponin, complete revascularization or left ventricular ejection fraction were not included in the analysis and may potentially acted as confounding factors.

Pathological mechanisms underlying increased adverse outcomes after AMI in patients with elevated MPV remains uncertain and multiple mechanisms may be involved. It has been reported the larger platelets have an increased metabolic activity and expression of inflammatory and coagulatory mediators, giving place to a proaggregating stage (6-9). This may therefore lead to an increased thrombogenic instability. Plaque rupture leading to intracoronary thrombus formation is commonly the precipitating event in ACS and, in addition to any other prothrombotic changes occurring in the atherosclerotic plaque, the presence of large and more reactive platelets is also likely to contribute to thrombosis and recurrent events (19).

From a clinical perspective, these results, alongside with prior evidence, support the role of MPV as a predictor of outcomes in AMI with ST segment elevation. MPV is easy to obtain and interpret, and routinely measured by automated cell counters as compared with other more complex markers of platelet activity. However, further studies are requested to compare MVP and other thrombosis and inflammatory biomarkers, define the exact cut-off value to predict an adverse outcome, assess if MPV might guide antiplatelet therapy selection and define if MPV improves risk stratification beyond current available scores.




Provenance: This is an invited Commentary commissioned by the Section Editor Xiaoyan Wang (PhD student in Cardiology, Shanghai Medical College, Fudan University, Shanghai, China).

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on:Sun XP, Li BY, Li J, et al. Impact of Mean Platelet Volume on Long-Term Mortality in Chinese Patients with ST-Elevation Myocardial Infarction. Sci Rep 2016;6:21350.


  1. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94. [Crossref] [PubMed]
  2. Martin JF, Plumb J, Kilbey RS, et al. Changes in volume and density of platelets in myocardial infarction. Br Med J (Clin Res Ed) 1983;287:456-9. [Crossref] [PubMed]
  3. Boos CJ, Lip GY. Assessment of mean platelet volume in coronary artery disease - what does it mean? Thromb Res 2007;120:11-3. [Crossref] [PubMed]
  4. Thompson CB, Jakubowski JA, Quinn PG, et al. Platelet size as a determinant of platelet function. J Lab Clin Med 1983;101:205-13. [PubMed]
  5. Karpatkin S, Strick N. Heterogeneity of human platelets. V. Differences in glycolytic and related enzymes with possible relation to platelet age. J Clin Invest 1972;51:1235-43. [Crossref] [PubMed]
  6. Martin JF, Shaw T, Heggie J, et al. Measurement of the density of human platelets and its relationship to volume. Br J Haematol 1983;54:337-52. [Crossref] [PubMed]
  7. Martin JF, Trowbridge EA, Salmon G, et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983;32:443-60. [Crossref] [PubMed]
  8. Thompson CB, Eaton KA, Princiotta SM, et al. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982;50:509-19. [Crossref] [PubMed]
  9. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994;24:69-72. [Crossref] [PubMed]
  10. Lippi G, Filippozzi L, Salvagno GL, et al. Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med 2009;133:1441-3. [PubMed]
  11. Chu H, Chen WL, Huang CC, et al. Diagnostic performance of mean platelet volume for patients with acute coronary syndrome visiting an emergency department with acute chest pain: the Chinese scenario. Emerg Med J 2011;28:569-74. [Crossref] [PubMed]
  12. Goncalves SC, Labinaz M, Le May M, et al. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol 2011;107:204-9. [Crossref] [PubMed]
  13. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005;46:284-90. [Crossref] [PubMed]
  14. Estévez-Loureiro R, Salgado-Fernández J, Marzoa-Rivas R, et al. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res 2009;124:536-40. [Crossref] [PubMed]
  15. Maden O, Kacmaz F, Selcuk MT, et al. Relationship of admission haematological indices with infarct-related artery patency in patients with acute ST-segment elevation myocardial infarction treated with primary angioplasty. Coron Artery Dis 2007;18:639-44. [Crossref] [PubMed]
  16. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010;8:148-56. [Crossref] [PubMed]
  17. Chung SP, Yune HY, Park YS, et al. Usefulness of mean platelet volume as a marker for clinical outcomes after out-of-hospital cardiac arrest: a retrospective cohort study. J Thromb Haemost 2016;14:2036-44. [Crossref] [PubMed]
  18. Sun XP, Li BY, Li J, et al. Impact of Mean Platelet Volume on Long-Term Mortality in Chinese Patients with ST-Elevation Myocardial Infarction. Sci Rep 2016;6:21350. [Crossref] [PubMed]
  19. Mathur A, Robinson MS, Cotton J, et al. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001;85:989-94. [PubMed]
Cite this article as: Benito-González T, Estévez-Loureiro R. Mean platelet volume: ready for prime time? J Thorac Dis 2016;8(11):E1481-E1483. doi: 10.21037/jtd.2016.11.99

Download Citation